Score only arrangements that pass the gates, and score the evidence as well as the proposal. The weights below are suggested starting values, not validated industry standards.
| Commercial criterion | Suggested weight | Evidence to use |
|---|---|---|
| Fulfilment and exception performance | 25% | Pilot data and comparable historical reports |
| Patient affordability across the expected mix | 20% | Matched quotations, eligibility and continuing-price scenarios |
| Clinic-controlled total cost | 20% | Fees, implementation, handling and commitment exposure |
| Workflow and reporting | 15% | Demonstrated events, exports and operational ownership |
| Continuity and exit readiness | 15% | Tested fallback and transition deliverables |
| Implementation burden | 5% | Named owners, dependencies and realistic milestones |
Use a separate evidence flag: verified, supplier-reported, not provided, or requires specialist review. Missing evidence is not automatically adverse evidence, but a critical unanswered question should block selection rather than receive an optimistic score.
Which contract protections differ by arrangement?
| Contract topic | Clinic-stock purchasing | Dispensing or access-service arrangement |
|---|---|---|
| Money at risk | Inventory title, deposits, credit, minimum orders and returnability | Implementation fees, service minimums, prepaid services and unreconciled patient transactions |
| Supply failure | Allocation, backorders, partial deliveries and replacement sourcing | Prescription acceptance, delayed checkout, fulfilment failures and rerouting support |
| Product integrity | Storage responsibility, shipment acceptance and quarantine | Investigation, patient contact, replacement and clinical escalation |
| Regulatory change | Stop-order rights and treatment of committed inventory | Suspension of affected routes, release from minimums and transition assistance |
| Exit | Inventory disposition, transaction records and outstanding credits | Exportable order history, open-case reconciliation and lawful prescription-transition support |
| Price changes | Notice, quote validity and interaction with broader commitments | Programme-change notification, service-fee changes and patient communication responsibilities |
These are negotiation requests, not assurances that every supplier will accept them. Seek counsel's review of remuneration, patient choice, data use, indemnities, liability limitations and the precise supply arrangement.
Explore the table row by row
A working view of the research
Fulfilment and exception performance
- Suggested weight
- 25%
- Evidence to use
- Pilot data and comparable historical reports
Sources cited on this page
See the section’s source register for the research context.
Section sources →